KTTA (Pasithea Therapeutics Corp.) מקדם שווי פעילות להכנסות

The lack of stable income and risks associated with psychiatric research are weighing on shares, and consequently, the EV-to-revenue ratio on GURU.Markets reflects current volatility, with the value holding at 0.00. The prospects for Pasithea Therapeutics (KTTA) rely on the success of macrophage inhibitors and M&A potential, while updated management strictly controls operating expenses to preserve liquidity.
Pasithea Therapeutics - פילוחים אנליטיים ומדדי מפתח (KTTA)

The balance between developing ketamine therapy clinics and creating neurofibromatosis drugs allows Pasithea Therapeutics (KTTA) to diversify its cash flows. By analyzing the enterprise value-to-sales multiple, an investor assesses the market value of the business, including debt, relative to revenue, where a sharp increase in the indicator signals inflated growth expectations and the risk of overpayment, calling into question the sustainability of the invested capital.